ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

INDP vs AQST // FREE CASH FLOW YIELD

Indaptus Therapeutics Inc. (NASDAQ) VS. Aquestive Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: INDP 3 — AQST 1
▲ FREE CASH FLOW YIELD LEADER: INDP
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDP VS. AQST) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC INDP AQST SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 58.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -2.89% -10.45% +7.56 INDP /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -22.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 AQST /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.2 37.5 +16.70 INDP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $513.0M $507.1M $5.9M INDP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR INDP REV AQST REV INDP GROSS % AQST GROSS % INDP FCF AQST FCF
FY 2025 $0 $44.5M — 58.3% -$14.8M -$53.0M
FY 2024 $0 $57.6M — 69.0% -$12.3M -$35.9M
FY 2023 $0 $50.6M — — -$13.4M -$6.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDP // BETA —
AQST // BETA —